Bicalutamide 150mg

  title={Bicalutamide 150mg},
  author={Keri David. Wellington and Susan J. Keam},
SummaryAlthough equivalence could not be established, progression-free and overall survival durations with bicalutamide were not significantly different from those with surgical or medical castration at a median 6.3 years’ follow-up in the combined results of the two monotherapy studies (n = 480). However, at 12 months’ follow-up, HR-QOL scores for sexual interest and physical capacity were higher in bicalutamide recipients than in men who had been castrated.AbstractBicalutamide (Casodex®) is a… 

Androgen Deprivation Therapy for Advanced Prostate Cancer

For men with castrate-resistant prostate cancer (CRPC), new treatment options with overall survival benefit are available including combined treatment with abiraterone and enzalutamide, nonhormonal therapies like chemotherapy with docetaxel and cabazitaxel, vaccine, and radium-223.

Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of age

Helical tomotherapy in super-elderly patients with localized and locally advanced prostate cancer had good biochemical control rates without severe late toxicity, and all patients improved with conservative therapy.

Review of HPLC and LC-MS/MS assays for the determination of various nonsteroidal anti-androgens used in the treatment of prostate cancer.

It was concluded that the published methodologies using either HPLC or LC-MS/MS are well suited for the quantification of NSAA inhibitors in various biological fluids to delineate pharmacokinetic data.

Identification of a Gene Signature to Aid Treatment Decisions by Integrated Analysis of Mutated Genes Between Primary and Metastatic Prostate Cancer

An integrated analysis of mutated genes between primary and metastatic prostate cancer and the prognostic value of riskscore is performed, which provides a novel assessment scheme to precisely select treatment strategies.

Detection of predictive markers for therapeutic stratification of salivary glands tumors.

This review represents an overview of the lesions of the salivary glands best characterized in terms of molecular aspects, focusing the attention on those markers and molecular alterations which can be important in the diagnosis as well as in the therapeutic stratification of these tumors.



Bicalutamide in Advanced Prostate Cancer

Bicalutamide, with its once-daily regimen and good tolerability, is an attractive option when combined with a GnRH agonist in patients with advanced prostate cancer who are suitable to receive maximum androgen blockade regimens.

Bicalutamide: in early-stage prostate cancer.

On two nonblind, randomised trials, bicalutamide 150 mg/day monotherapy was as effective as medical or surgical castration in terms of overall survival in patients with locally advanced nonmetastatic prostate cancer.

Drug Evaluation Oncologic, Endocrine & Metabolic: Bicalutamide (Casodex™)

Results of monotherapy studies reveal that 50 mg of bicalutamide is less effective than castration in patients with advanced disease; Phase III monotherapy Studies are ongoing to compare 150 mg ofbicalutamia with castration.

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

Bicalutamide (150 mg) provides significant benefit in patients with locally advanced prostate cancer, and in previously untreated patients there may be a tumor burden below which endocrine therapy provides no benefit or may even decrease survival.

Bicalutamide Pharmacokinetics and Metabolism

Bicalutamide is used once daily as monotherapy for the treatment of early (localised or locally advanced) nonmetastatic prostate cancer and in combination with a luteinising hormone-releasing hormone analogue or surgical castration for the Treatment of advanced prostate cancer.

Bicalutamide: clinical pharmacokinetics and metabolism.

Bicalutamide is a nonsteroidal pure antiandrogen given at a dosage of 150 mg once daily as monotherapy for the treatment of early (localised or locally advanced) nonmetastatic prostate cancer and has the potential to inhibit CYP3A4 and, to a lesser extent, CYP2C9, 2C19 and 2D6.

Treatment of Locally Advanced Prostate Cancer – A New Role for Antiandrogen Monotherapy?

In the setting of previously untreated locally advanced disease, pooled mature data from two major studies indicate no significant difference in survival outcome between bicalutamide (‘Casodex’) 150 mg and castration.